enGene Holdings IncNASDAQ:ENGN
- LAST PRICE7.6700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots6.2000/ 1
- Ask / Lots8.2500/ 5
- Open / Previous Close--- / 7.6700
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ENGN |
|---|---|---|
| 09:32 ET | 308 | 7.7999 |
| 09:53 ET | 1300 | 7.645 |
| 10:02 ET | 850 | 7.64 |
| 10:09 ET | 100 | 7.645 |
| 10:49 ET | 500 | 7.7718 |
| 11:05 ET | 20564 | 7.64 |
| 11:09 ET | 7824 | 7.595 |
| 11:34 ET | 100 | 7.52 |
| 11:36 ET | 100 | 7.4667 |
| 11:38 ET | 200 | 7.53 |
| 12:44 ET | 3078 | 7.5 |
| 12:48 ET | 100 | 7.54 |
| 01:00 ET | 400 | 7.495 |
| 01:09 ET | 700 | 7.46 |
| 01:13 ET | 499 | 7.51 |
| 01:54 ET | 200 | 7.49 |
| 02:45 ET | 1000 | 7.5134 |
| 03:01 ET | 500 | 7.5001 |
| 03:06 ET | 100 | 7.54 |
| 03:08 ET | 100 | 7.54 |
| 03:10 ET | 500 | 7.65 |
| 03:12 ET | 4490 | 7.5799 |
| 03:24 ET | 200 | 7.734 |
| 03:44 ET | 4195 | 7.86 |
| 03:46 ET | 400 | 7.925 |
| 03:53 ET | 362 | 7.89 |
| 03:57 ET | 300 | 7.8615 |
| 04:00 ET | 2963 | 7.67 |
Nov 18, 2024
DJ enGene Holdings Initiated at Market Outperform by JMP Securities, from 4:48AM ET on Monday Nov 18, 2024 by Dow Jones
4:48AM ET on Monday Nov 18, 2024 by Dow Jones
Nov 5, 2024
enGene to Participate in Guggenheim's Inaugural Healthcare Innovation Conference, from 8:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
8:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
Oct 25, 2024
DJ EnGene Holdings Shares Rise After $60M Private Placement, from 8:52AM ET on Friday Oct 25, 2024 by Dow Jones
8:52AM ET on Friday Oct 25, 2024 by Dow JonesenGene Announces $60 Million Private Placement Financing, from 8:00AM ET on Friday Oct 25, 2024 by Dow Jones
8:00AM ET on Friday Oct 25, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
enGene Holdings Inc | 339.1M | -1.6x | --- |
Jasper Therapeutics Inc | 327.6M | -4.6x | --- |
Q32 Bio Inc | 329.4M | -3.6x | --- |
Prime Medicine Inc | 356.5M | -1.4x | --- |
Design Therapeutics Inc | 315.4M | -6.6x | --- |
Kodiak Sciences Inc | 310.4M | -1.6x | --- |
Company Information
enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company’s proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Company’s DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.
Contact Information
- Headquarters
- 4868 Rue Levy, Suite 220SAINT-LAURENT, QC, Canada H4R 2P1
- Phone
- 514-332-4888
- Fax
- ---
Executives
- Independent Chairman of the Board
- Richard Glickman
- Chief Executive Officer, Director
- Ronald Cooper
- Chief Financial Officer, Head - Business Development
- Ryan Daws
- Chief Technology Officer
- Joan Connolly
- Chief Scientific Officer
- Anthony Cheung
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $339.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 44.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-4.77 |
Book Value | $3.12 |
P/E Ratio | -1.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
